Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
BACKGROUND: A range of safe and effective vaccines against SARS CoV 2 are needed to address the COVID 19 pandemic. We aimed to assess the safety and efficacy of the COVID-19 vaccine SCB-2019. METHODS: This ongoing phase 2 and 3 double-blind, placebo-controlled trial was done in adults aged 18 years and older who were in good health or with a stable chronic health condition, at 31 sites in five countries (Belgium, Brazil, Colombia, Philippines, and South Africa). The participants were randomly assigned 1:1 using a centralised internet randomisation system to receive two 0·5 mL intramuscular dos... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2022 |
Verlag/Hrsg.: |
Elsevier
|
Schlagwörter: | Adjuvants / Immunologic / Adolescent / Adult / Aged / Alum Compounds / Belgium / Brazil / COVID-19 / COVID-19 Vaccines / Colombia / Double-Blind Method / Female / Humans / Male / Middle Aged / Oligodeoxyribonucleotides / Philippines / Protein Multimerization / Recombinant Proteins / Risk / SARS-CoV-2 / South Africa / Spike Glycoprotein / Coronavirus / Vaccine Efficacy / Young Adult |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26588431 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/278138 |